Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-34246925

ABSTRACT

The additive effects of prostaglandin (PG)-EP2 agonists on a PG-FP agonist toward adipogenesis in two- or three-dimension (2D or 3D) cultures of 3T3-L1 cells was examined by lipid staining, the mRNA expression of adipogenesis related genes, and extracellular matrixes (ECMs) including collagen molecules (Col) -1, -4 and -6, and fibronectin (Fn), and the sizes and physical properties of 3D sphenoids, as measured by a micro-squeezer. The results indicate that adipogenesis induced 1) an enlargement in the sizes of 3D sphenoids, 2) a substantial enhancement in lipid staining, the expression of the PParγ, Ap2 and Leptin genes, and 3) a significant decrease in the stiffness of the 3D sphenoids. These effects were inhibited by bimatoprost acid (BIM-A), but 4) adipogenesis induced significant down-regulation of Col1 and Fn, and the significant up-regulation of the Col4 and Col6 genes were unchanged by BIM-A. On the addition of an EP2 agonist, such as omidenepag (OMD) or butaprost (Buta), to BIM-A, 1) the sizes of the 3D sphenoids were further decreased, 2) lipid staining was decreased (2D; OMD, 3D; Buta) 3) the stiffness of the 3D sphenoids was increased by Buta, 4) the expression of PParγ was up-regulated (2D; Buta) or unchanged (3D), the expression of Ap2 was down-regulated (2D; OMD) or up-regulated (3D; Buta), and the expression of Leptin was increased (2D), 5) the expression of all four (OMD) or all except Col4 (buta) in 2D, and Col1and Col4 (OMD) in 3D were up-regulated. These collective findings indicate that the addition of an EP2 agonist, OMD or Buta significantly modulated the BIM-A induced suppression of adipogenesis as well as physical properties of 2D and 3D cultured 3T3-L1 cells in different manners.


Subject(s)
Adipogenesis/drug effects , Alprostadil/analogs & derivatives , Bimatoprost/pharmacology , Fatty Acid-Binding Proteins/drug effects , Glycine/analogs & derivatives , Leptin/genetics , PPAR gamma/drug effects , Pyrazoles/pharmacology , Pyridines/pharmacology , Receptors, Prostaglandin E, EP2 Subtype/agonists , Receptors, Prostaglandin/agonists , 3T3-L1 Cells , Adipogenesis/genetics , Alprostadil/pharmacology , Animals , Cell Culture Techniques, Three Dimensional , Collagen Type I/drug effects , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type IV/drug effects , Collagen Type IV/genetics , Collagen Type IV/metabolism , Collagen Type VI/drug effects , Collagen Type VI/genetics , Collagen Type VI/metabolism , Drug Synergism , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Fatty Acid-Binding Proteins/genetics , Fatty Acid-Binding Proteins/metabolism , Fibronectins/drug effects , Fibronectins/genetics , Fibronectins/metabolism , Glycine/pharmacology , Leptin/metabolism , Mice , PPAR gamma/genetics , PPAR gamma/metabolism , Spheroids, Cellular/drug effects , Spheroids, Cellular/metabolism
2.
J Periodontal Res ; 44(6): 736-43, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19438976

ABSTRACT

BACKGROUND AND OBJECTIVE: Oral submucous fibrosis, a disease of collagen disorder, has been attributed to arecoline present in the saliva of betel quid chewers. However, the molecular basis of the action of arecoline in the pathogenesis of oral submucous fibrosis is poorly understood. The basic aim of our study was to elucidate the mechanism underlying the action of arecoline on the expression of genes in oral fibroblasts. MATERIAL AND METHODS: Human keratinocytes (HaCaT cells) and primary human gingival fibroblasts were treated with arecoline in combination with various pathway inhibitors, and the expression of transforming growth factor-beta isoform genes and of collagen isoforms was assessed using reverse transcription-polymerase chain reaction analysis. RESULTS: We observed the induction of transforming growth factor-beta2 by arecoline in HaCaT cells and this induction was found to be caused by activation of the M-3 muscarinic acid receptor via the induction of calcium and the protein kinase C pathway. Most importantly, we showed that transforming growth factor-beta2 was significantly overexpressed in oral submucous fibrosis tissues (p = 0.008), with a median of 2.13 (n = 21) compared with 0.75 (n = 18) in normal buccal mucosal tissues. Furthermore, arecoline down-regulated the expression of collagens 1A1 and 3A1 in human primary gingival fibroblasts; however these collagens were induced by arecoline in the presence of spent medium of cultured human keratinocytes. Treatment with a transforming growth factor-beta blocker, transforming growth factor-beta1 latency-associated peptide, reversed this up-regulation of collagen, suggesting a role for profibrotic cytokines, such as transforming growth factor-beta, in the induction of collagens. CONCLUSION: Taken together, our data highlight the importance of arecolineinduced epithelial changes in the pathogenesis of oral submucous fibrosis.


Subject(s)
Arecoline/pharmacology , Cholinergic Agonists/pharmacology , Extracellular Matrix/drug effects , Fibroblasts/drug effects , Gingiva/drug effects , Keratinocytes/drug effects , Cell Line , Chelating Agents/pharmacology , Collagen/drug effects , Collagen/genetics , Collagen Type I/drug effects , Collagen Type I/genetics , Collagen Type I, alpha 1 Chain , Collagen Type III/drug effects , Collagen Type III/genetics , Collagen Type IV/drug effects , Collagen Type IV/genetics , Collagen Type VI/drug effects , Collagen Type VI/genetics , Collagen Type VII/drug effects , Collagen Type VII/genetics , Down-Regulation , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Extracellular Matrix/genetics , Gingiva/cytology , Humans , Mouth Mucosa/pathology , Oral Submucous Fibrosis/genetics , Oral Submucous Fibrosis/pathology , Protein Isoforms/drug effects , Protein Isoforms/genetics , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/drug effects , Protein Kinase C/genetics , Receptor, Muscarinic M3/drug effects , Receptor, Muscarinic M3/genetics , Staurosporine/pharmacology , Transforming Growth Factor beta1/pharmacology , Transforming Growth Factor beta2/drug effects , Transforming Growth Factor beta2/genetics
3.
Eur Respir J ; 20(2): 280-5, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12212956

ABSTRACT

Increased or altered collagen deposition in the airway wall is one of the characteristics of airway remodelling in asthma. The mechanisms underlying this increase, and its functional consequences remain to be established further. Representative in vivo animal models might be useful in this respect. In the present study, collagen deposition after prolonged allergen exposure was characterised in the airway wall of Brown Norway rats. Sensitised rats were repeatedly exposed to ovalbumin (OA) or phosphate-buffered saline during 2 and 12 weeks. The deposition of collagen type I, III, IV, V and VI was not altered in animals exposed to OA for 2 weeks. After 12 weeks of OA exposure, more collagen type I was deposited in the inner and outer airway wall and more type V and VI collagen was observed in the outer airway wall. At 12 weeks the number of vessels, identified via type IV collagen staining was not increased, but the total vessel area was. In conclusion, prolonged allergen exposure in sensitised rats is associated with enhanced deposition of type I, V and VI collagens and increased vascularity. This suggests that some aspects of airway remodelling in asthma could be driven by long-term allergen exposure.


Subject(s)
Allergens/administration & dosage , Allergens/pharmacology , Asthma/pathology , Collagen Type IV/analysis , Collagen Type IV/drug effects , Collagen Type VI/analysis , Collagen Type VI/drug effects , Fibrillar Collagens/analysis , Fibrillar Collagens/drug effects , Immunization , Lung/drug effects , Lung/pathology , Ovalbumin/administration & dosage , Ovalbumin/pharmacology , Allergens/immunology , Animals , Asthma/immunology , Collagen Type IV/immunology , Collagen Type VI/immunology , Disease Models, Animal , Dose-Response Relationship, Drug , Fibrillar Collagens/immunology , Lung/immunology , Male , Ovalbumin/immunology , Rats , Time Factors
4.
Connect Tissue Res ; 31(2): 161-70, 1995.
Article in English | MEDLINE | ID: mdl-15612332

ABSTRACT

The biosynthesis of type VI collagen was studied in human glioblastoma cell line, U-87 MG. The effects of ascorbic acid on type VI collagen synthesis and secretion were investigated. After ascorbic acid treatment, type VI collagen in cell layers increased from 4.48% in control to 6.63% in the ascorbic acid treated cultures, an increase of 48%. The effect of ascorbic acid on type VI collagen synthesized by glioblastoma cells was lower than that reported for osteosarcoma cells (Engvall et al., 1986). The reason for these differences is still under investigation. The function of type VI collagen in glioblastoma cells is still unknown. We utilized the collagen gel system to elucidate the possible roles of type VI collagen in glioblastoma cells in vitro. Glioblastoma cells in collagen gels showed a stellate shape with long, branched processes in all directions. The strong positive reactivity of type VI collagen detected on cell bodies and cell processes by anti-type VI collagen antibody indicated that this specific collagen was associated with cell surfaces and processes, without releasing or diffusing into the gels. Type VI collagen was directly involved in the cell process extension. When living cells were treated with anti-type VI collagen antibody, a variation of cell morphology was observed. Instead of a stellate shape with processes, cells formed clusters without or with very short processes. These data suggest that type VI collagen, synthesized and secreted by glioblastoma cells, may play a role in tumor cell adhesion and spreading, and enhance cell process extension, penetration, and invasion into collagen gels.


Subject(s)
Bone Neoplasms/metabolism , Brain Neoplasms/metabolism , Collagen Type VI/biosynthesis , Extracellular Matrix/metabolism , Glioblastoma/metabolism , Neoplasm Invasiveness/physiopathology , Osteosarcoma/metabolism , Antibodies/pharmacology , Artificial Organs , Ascorbic Acid/pharmacology , Bone Neoplasms/physiopathology , Brain Neoplasms/physiopathology , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cell Membrane/metabolism , Cell Shape/drug effects , Cell Shape/physiology , Cell Surface Extensions/drug effects , Cell Surface Extensions/metabolism , Collagen Type VI/drug effects , Collagen Type VI/metabolism , Gels , Glioblastoma/physiopathology , Humans , Models, Biological , Osteosarcoma/physiopathology , Up-Regulation/drug effects , Up-Regulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...